Linker ID	LIN0GZQER
Linker Name	mp-dLAE-PABC
Antibody-Linker Relation	Cleavable

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	8.00%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	65.00%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	72.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	84.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	87.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	162 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 2000 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.32 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	32.00%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	72.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	78.00%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	79.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	86.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	21.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	31.00 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 2000 nM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	33.00%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	72.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	83.00%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	83.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	86.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	88.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	104 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.10 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.64 uM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	36.00%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	74.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	76.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	85.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	85.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	90.00%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	60.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	64.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	369 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	678 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 2000 nM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	41.00%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	71.00%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	77.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	78.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	81.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	85.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.00 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	27.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 2000 nM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	46.00%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	75.00%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	76.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	78.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	81.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.00 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	25.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.37 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	48.00%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	77.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	84.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	87.00%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	87.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	88.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	56.00 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	215 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.62 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	50.00%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	70.00%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	75.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	85.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.00 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.41 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	69.00%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	73.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	83.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	85.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	87.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	95.00%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.00 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	52.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	856 nM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	74.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	81.00%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	84.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	87.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	89.00%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	93.00%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.00 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	52.00 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	100 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.14 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Ref 1	Anti-cd228 antibodies and antibody-drug conjugates; 2022-02-10.